Skip to content
DataLookout
Menu

Also listed under Skin Diseases

ClinicalTrials.gov term: Scleroderma, Systemic

Scleroderma clinical trials

Get alerts when Scleroderma trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

17 trials changed in the last 30 days: 1 stopped, 11 with notable changes, 5 with minor changes only.

  1. Minor: ROSY-S · Rollover Study · Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment Trial sites expanded: 153 → 166 locations AstraZenecaPhase 3 NCT07691970
  2. Minor: Ianalumab · Diffuse Cutaneous Systemic Sclerosis Trial sites reduced: 106 → 96 locations Novartis PharmaceuticalsPhase 2 NCT06470048
  3. Minor: 2 trials marked Unknown by the registry's verification sweep Changed Registry verification sweep2 trials
    1. Minor: BAH242 · Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting Essen BiotechPhase 1/2 NCT06350110
    2. Minor: RAISE · Rare AutoImmune SElf-management Programme Development Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting University of the West of EnglandNot specified NCT06642870
  4. Notable: Hyaluronidase Injections for Sclerodactyly · Scleroderma Primary endpoint(s) modified Stanford UniversityPhase 2 NCT07916324
  5. Notable: Healthy Adult Participants and · Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body Primary endpoint(s) modified Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 1 NCT07649265
  6. Notable: Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images Primary and study completion pushed from Jul 2026 to May 2027 Yale UniversityNot specified NCT07228429
  7. Notable: AURORA · AZD0120 in Autoimmune Diseases Phase changed: Phase 1 → Phase 1/2 AstraZenecaPhase 1/2 NCT07295847
  8. Notable: UVA-1 · Skin Tightening and Improvement of Hand Function in Scleroderma Results posted: Nov 2, 2026 University of UtahNot applicable NCT04875078
  9. Minor: NKX019 · Immune-Mediated Diseases (Ntrust-2) Trial sites reduced: 18 → 12 locations Nkarta, Inc.Phase 1/2 NCT06733935
  10. Notable: hiPSSS · Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs) Recruitment opened University Hospital, MontpellierNot applicable NCT07650565
  11. Notable: ATTRACT · ATG-201 · Autoimmune Diseases Recruitment opened Antengene Biologics LimitedPhase 1 NCT07732309
  12. Notable: Patient Reported Outcomes With UVA-1 Therapy · Sclerosing Skin Diseases Primary and study completion pushed from Jun 2026 to Jun 2027 University of UtahNot applicable NCT04922736
  13. Notable: YTS109 Cell Injection · Recurrent/Refractory Autoimmune Disease Primary and study completion dates pushed to Apr 21, 2027 China Immunotech (Beijing) Biotechnology Co., Ltd.Not applicable NCT06379646
  14. Notable: CRT-402 in Refractory Autoimmune Disease Recruitment opened Myeloid TherapeuticsPhase 1/2 NCT07778446
  15. Notable: YTS109 Cell in R/R Autoimmune Diseases Primary completion pushed from May 19, 2026 to May 19, 2027 China Immunotech (Beijing) Biotechnology Co., Ltd.Phase 1 NCT06978647
  16. Stopped: Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis Trial terminated The Foundation for Orthopaedics and Regenerative MedicinePhase 1 NCT05016804
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-18 NCT07946367 Dual-targeting of B & T Cell Pathways Evaluation Trial Diabetes Free, Inc. new Phase 1/2
2026-11-09 NCT07925619 Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital… Pharmosa Biopharm Inc. new Phase 2
2026-10-30 NCT07906145 A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases Shanghai Qilu Pharmaceutical Research and Development Center LTD new Phase 1
2026-10-30 NCT07908108 Cross-cultural Adaptation and Validation of the Localised Scleroderma Quality of Life… Istituto Giannina Gaslini new
2026-10-02 NCT07854483 C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in… AbelZeta Inc. new Phase 1
2026-09-30 NCT07849673 Improving ILD Screening in Patients With RA and SSc Using EHR-Embedded CDS and PRO Tools Foundation for Advancing Science Technology Education and Research new
2026-09-15 NCT07821398 Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung… Bastiaan Driehuys new Phase 2
2026-09-14 NCT07817160 Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis Biruni University new
2026-09-08 NCT07806045 Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement Qiubai Li new Early Phase 1
2026-08-21 NCT07778446 A Study to Test CRT-402 in Refractory Autoimmune Disease Myeloid Therapeutics new Phase 1/2

Active trials by phase

Early Phase 1
23
Phase 1
41
Phase 1/2
22
Phase 2
38
Phase 2/3
4
Phase 3
13
Phase 4
5
Not charted: 113 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Scleroderma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free

Narrower conditions

Active trials